Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PLIANT THERAPEUTICS, INC.PLRX · Entity 7022 | Chief Financial Officer | April 17, 2026 | April 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PLIANT THERAPEUTICS, INC.
Report date April 17, 2026 · Filed April 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.08 · Expires 2029-01-24 | Direct | 0 |
Reported balance
After 2026-04-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-17 · Disposition to issuer · Disposed 76,047 · Balance 0 F1: On April 17, 2026, the Issuer's board of directors approved an option repricing (the "Repricing"), effective April 17, 2026 (the "Effective Date"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged. F2: The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the "2015 Plan"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the "2020 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date. F3: The expiration date has been updated from the Form 3 originally filed on June 2, 2020 from January 23, 2029 to the correct expiration date of January 24, 2029. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.33 · Expires 2029-01-24 | Direct | 76,047 |
Reported balance
After 2026-04-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-17 · Grant · Acquired 76,047 · Balance 76,047 F4: The closing price per share of the Issuer's common stock on the Effective Date. Under the terms of the Repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends on the earliest of the following: (i) the eighteen-month anniversary of the Effective Date; (ii) the consummation of a Corporate Transaction (as defined by the 2015 Plan) or a Sale Event (as defined by the 2020 Plan); and (iii) the Reporting Person's (a) termination without cause (as defined in the Reporting Person's severance plan) or due to a reduction in force, (b) death or termination due to disability, or (c) resignation from service for good reason (as defined in the Reporting Person's severance plan). F5: The repriced options will also revert to its original exercise price if the Reporting Person (i) is terminated for cause (as defined in the Reporting Person's severance Plan) or (ii) resigns prior to the end of the Retention Period, except for good reason (as defined in the Reporting Person's severance plan). F1: On April 17, 2026, the Issuer's board of directors approved an option repricing (the "Repricing"), effective April 17, 2026 (the "Effective Date"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged. F2: The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the "2015 Plan"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the "2020 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date. F3: The expiration date has been updated from the Form 3 originally filed on June 2, 2020 from January 23, 2029 to the correct expiration date of January 24, 2029. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.22 · Expires 2030-03-31 | Direct | 0 |
Reported balance
After 2026-04-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-04-17 · Disposition to issuer · Disposed 18,198 · Balance 0 F1: On April 17, 2026, the Issuer's board of directors approved an option repricing (the "Repricing"), effective April 17, 2026 (the "Effective Date"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged. F2: The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the "2015 Plan"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the "2020 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date. F6: The expiration date has been updated from the Form 3 originally filed on June 2, 2020 from March 30, 2030 to the correct expiration date of March 31, 2030. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.33 · Expires 2030-03-31 | Direct | 18,198 |
Reported balance
After 2026-04-17 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-04-17 · Grant · Acquired 18,198 · Balance 18,198 F4: The closing price per share of the Issuer's common stock on the Effective Date. Under the terms of the Repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends on the earliest of the following: (i) the eighteen-month anniversary of the Effective Date; (ii) the consummation of a Corporate Transaction (as defined by the 2015 Plan) or a Sale Event (as defined by the 2020 Plan); and (iii) the Reporting Person's (a) termination without cause (as defined in the Reporting Person's severance plan) or due to a reduction in force, (b) death or termination due to disability, or (c) resignation from service for good reason (as defined in the Reporting Person's severance plan). F5: The repriced options will also revert to its original exercise price if the Reporting Person (i) is terminated for cause (as defined in the Reporting Person's severance Plan) or (ii) resigns prior to the end of the Retention Period, except for good reason (as defined in the Reporting Person's severance plan). F1: On April 17, 2026, the Issuer's board of directors approved an option repricing (the "Repricing"), effective April 17, 2026 (the "Effective Date"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged. F2: The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the "2015 Plan"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the "2020 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date. F6: The expiration date has been updated from the Form 3 originally filed on June 2, 2020 from March 30, 2030 to the correct expiration date of March 31, 2030. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.50 · Expires 2031-01-23 | Direct | 0 |
Reported balance
After 2026-04-17 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-04-17 · Disposition to issuer · Disposed 74,250 · Balance 0 F1: On April 17, 2026, the Issuer's board of directors approved an option repricing (the "Repricing"), effective April 17, 2026 (the "Effective Date"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged. F2: The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the "2015 Plan"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the "2020 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date. F7: The expiration date has been updated from the Form 4 originally filed on January 26, 2021 from January 22, 2031 to the correct expiration date of January 23, 2031. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.33 · Expires 2031-01-23 | Direct | 74,250 |
Reported balance
After 2026-04-17 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-04-17 · Grant · Acquired 74,250 · Balance 74,250 F4: The closing price per share of the Issuer's common stock on the Effective Date. Under the terms of the Repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends on the earliest of the following: (i) the eighteen-month anniversary of the Effective Date; (ii) the consummation of a Corporate Transaction (as defined by the 2015 Plan) or a Sale Event (as defined by the 2020 Plan); and (iii) the Reporting Person's (a) termination without cause (as defined in the Reporting Person's severance plan) or due to a reduction in force, (b) death or termination due to disability, or (c) resignation from service for good reason (as defined in the Reporting Person's severance plan). F5: The repriced options will also revert to its original exercise price if the Reporting Person (i) is terminated for cause (as defined in the Reporting Person's severance Plan) or (ii) resigns prior to the end of the Retention Period, except for good reason (as defined in the Reporting Person's severance plan). F1: On April 17, 2026, the Issuer's board of directors approved an option repricing (the "Repricing"), effective April 17, 2026 (the "Effective Date"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged. F2: The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the "2015 Plan"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the "2020 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date. F7: The expiration date has been updated from the Form 4 originally filed on January 26, 2021 from January 22, 2031 to the correct expiration date of January 23, 2031. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.86 · Expires 2032-01-26 | Direct | 0 |
Reported balance
After 2026-04-17 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-04-17 · Disposition to issuer · Disposed 124,000 · Balance 0 F1: On April 17, 2026, the Issuer's board of directors approved an option repricing (the "Repricing"), effective April 17, 2026 (the "Effective Date"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged. F2: The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the "2015 Plan"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the "2020 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date. F8: The expiration date has been updated from the Form 4 originally filed on February 2, 2022 from January 25, 2032 to the correct expiration date of January 26, 2032. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.33 · Expires 2032-01-26 | Direct | 124,000 |
Reported balance
After 2026-04-17 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-04-17 · Grant · Acquired 124,000 · Balance 124,000 F4: The closing price per share of the Issuer's common stock on the Effective Date. Under the terms of the Repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends on the earliest of the following: (i) the eighteen-month anniversary of the Effective Date; (ii) the consummation of a Corporate Transaction (as defined by the 2015 Plan) or a Sale Event (as defined by the 2020 Plan); and (iii) the Reporting Person's (a) termination without cause (as defined in the Reporting Person's severance plan) or due to a reduction in force, (b) death or termination due to disability, or (c) resignation from service for good reason (as defined in the Reporting Person's severance plan). F5: The repriced options will also revert to its original exercise price if the Reporting Person (i) is terminated for cause (as defined in the Reporting Person's severance Plan) or (ii) resigns prior to the end of the Retention Period, except for good reason (as defined in the Reporting Person's severance plan). F1: On April 17, 2026, the Issuer's board of directors approved an option repricing (the "Repricing"), effective April 17, 2026 (the "Effective Date"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged. F2: The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the "2015 Plan"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the "2020 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date. F8: The expiration date has been updated from the Form 4 originally filed on February 2, 2022 from January 25, 2032 to the correct expiration date of January 26, 2032. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.65 · Expires 2033-01-25 | Direct | 0 |
Reported balance
After 2026-04-17 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-04-17 · Disposition to issuer · Disposed 76,200 · Balance 0 F1: On April 17, 2026, the Issuer's board of directors approved an option repricing (the "Repricing"), effective April 17, 2026 (the "Effective Date"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged. F2: The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the "2015 Plan"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the "2020 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date. F9: The expiration date has been updated from the Form 4 originally filed on January 27, 2023 from January 24, 2033 to the correct expiration date of January 25, 2033. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.33 · Expires 2033-01-25 | Direct | 76,200 |
Reported balance
After 2026-04-17 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-04-17 · Grant · Acquired 76,200 · Balance 76,200 F4: The closing price per share of the Issuer's common stock on the Effective Date. Under the terms of the Repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends on the earliest of the following: (i) the eighteen-month anniversary of the Effective Date; (ii) the consummation of a Corporate Transaction (as defined by the 2015 Plan) or a Sale Event (as defined by the 2020 Plan); and (iii) the Reporting Person's (a) termination without cause (as defined in the Reporting Person's severance plan) or due to a reduction in force, (b) death or termination due to disability, or (c) resignation from service for good reason (as defined in the Reporting Person's severance plan). F5: The repriced options will also revert to its original exercise price if the Reporting Person (i) is terminated for cause (as defined in the Reporting Person's severance Plan) or (ii) resigns prior to the end of the Retention Period, except for good reason (as defined in the Reporting Person's severance plan). F1: On April 17, 2026, the Issuer's board of directors approved an option repricing (the "Repricing"), effective April 17, 2026 (the "Effective Date"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged. F2: The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the "2015 Plan"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the "2020 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date. F9: The expiration date has been updated from the Form 4 originally filed on January 27, 2023 from January 24, 2033 to the correct expiration date of January 25, 2033. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.44 · Expires 2034-01-23 | Direct | 0 |
Reported balance
After 2026-04-17 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-04-17 · Disposition to issuer · Disposed 110,500 · Balance 0 F1: On April 17, 2026, the Issuer's board of directors approved an option repricing (the "Repricing"), effective April 17, 2026 (the "Effective Date"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged. F2: The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the "2015 Plan"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the "2020 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.33 · Expires 2034-01-23 | Direct | 110,500 |
Reported balance
After 2026-04-17 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-04-17 · Grant · Acquired 110,500 · Balance 110,500 F4: The closing price per share of the Issuer's common stock on the Effective Date. Under the terms of the Repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends on the earliest of the following: (i) the eighteen-month anniversary of the Effective Date; (ii) the consummation of a Corporate Transaction (as defined by the 2015 Plan) or a Sale Event (as defined by the 2020 Plan); and (iii) the Reporting Person's (a) termination without cause (as defined in the Reporting Person's severance plan) or due to a reduction in force, (b) death or termination due to disability, or (c) resignation from service for good reason (as defined in the Reporting Person's severance plan). F5: The repriced options will also revert to its original exercise price if the Reporting Person (i) is terminated for cause (as defined in the Reporting Person's severance Plan) or (ii) resigns prior to the end of the Retention Period, except for good reason (as defined in the Reporting Person's severance plan). F1: On April 17, 2026, the Issuer's board of directors approved an option repricing (the "Repricing"), effective April 17, 2026 (the "Effective Date"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged. F2: The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the "2015 Plan"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the "2020 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.14 · Expires 2035-01-23 | Direct | 0 |
Reported balance
After 2026-04-17 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2026-04-17 · Disposition to issuer · Disposed 113,300 · Balance 0 F1: On April 17, 2026, the Issuer's board of directors approved an option repricing (the "Repricing"), effective April 17, 2026 (the "Effective Date"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged. F2: The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the "2015 Plan"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the "2020 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.33 · Expires 2035-01-23 | Direct | 113,300 |
Reported balance
After 2026-04-17 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2026-04-17 · Grant · Acquired 113,300 · Balance 113,300 F4: The closing price per share of the Issuer's common stock on the Effective Date. Under the terms of the Repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends on the earliest of the following: (i) the eighteen-month anniversary of the Effective Date; (ii) the consummation of a Corporate Transaction (as defined by the 2015 Plan) or a Sale Event (as defined by the 2020 Plan); and (iii) the Reporting Person's (a) termination without cause (as defined in the Reporting Person's severance plan) or due to a reduction in force, (b) death or termination due to disability, or (c) resignation from service for good reason (as defined in the Reporting Person's severance plan). F5: The repriced options will also revert to its original exercise price if the Reporting Person (i) is terminated for cause (as defined in the Reporting Person's severance Plan) or (ii) resigns prior to the end of the Retention Period, except for good reason (as defined in the Reporting Person's severance plan). F1: On April 17, 2026, the Issuer's board of directors approved an option repricing (the "Repricing"), effective April 17, 2026 (the "Effective Date"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged. F2: The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the "2015 Plan"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the "2020 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: On April 17, 2026, the Issuer's board of directors approved an option repricing (the "Repricing"), effective April 17, 2026 (the "Effective Date"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged.
F2: The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the "2015 Plan"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the "2020 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date.
F3: The expiration date has been updated from the Form 3 originally filed on June 2, 2020 from January 23, 2029 to the correct expiration date of January 24, 2029.
F4: The closing price per share of the Issuer's common stock on the Effective Date. Under the terms of the Repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends on the earliest of the following: (i) the eighteen-month anniversary of the Effective Date; (ii) the consummation of a Corporate Transaction (as defined by the 2015 Plan) or a Sale Event (as defined by the 2020 Plan); and (iii) the Reporting Person's (a) termination without cause (as defined in the Reporting Person's severance plan) or due to a reduction in force, (b) death or termination due to disability, or (c) resignation from service for good reason (as defined in the Reporting Person's severance plan).
F5: The repriced options will also revert to its original exercise price if the Reporting Person (i) is terminated for cause (as defined in the Reporting Person's severance Plan) or (ii) resigns prior to the end of the Retention Period, except for good reason (as defined in the Reporting Person's severance plan).
F6: The expiration date has been updated from the Form 3 originally filed on June 2, 2020 from March 30, 2030 to the correct expiration date of March 31, 2030.
F7: The expiration date has been updated from the Form 4 originally filed on January 26, 2021 from January 22, 2031 to the correct expiration date of January 23, 2031.
F8: The expiration date has been updated from the Form 4 originally filed on February 2, 2022 from January 25, 2032 to the correct expiration date of January 26, 2032.
F9: The expiration date has been updated from the Form 4 originally filed on January 27, 2023 from January 24, 2033 to the correct expiration date of January 25, 2033.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 17, 2026 Filed Apr 17, 2026 20:42 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | GrantStock Option (Right to Buy) · Derivative | 113,300 | $0.00 Strike: $1.33 | $0.00 |
DisclosureSEC source: 0001746473-26-000054 · wk-form4_1776458561.xml · derivative · entry 14 Cummings Keith Lamont · CIK 0001809204 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,300 Underlying: Common Stock · 113,300 shares Expires 2035-01-23 F4 · derivative.exercise_price: The closing price per share of the Issuer's common stock on the Effective Date. Under the terms of the Repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends on the earliest of the following: (i) the eighteen-month anniversary of the Effective Date; (ii) the consummation of a Corporate Transaction (as defined by the 2015 Plan) or a Sale Event (as defined by the 2020 Plan); and (iii) the Reporting Person's (a) termination without cause (as defined in the Reporting Person's severance plan) or due to a reduction in force, (b) death or termination due to disability, or (c) resignation from service for good reason (as defined in the Reporting Person's severance plan). F5 · derivative.exercise_price: The repriced options will also revert to its original exercise price if the Reporting Person (i) is terminated for cause (as defined in the Reporting Person's severance Plan) or (ii) resigns prior to the end of the Retention Period, except for good reason (as defined in the Reporting Person's severance plan). F1 · kind: On April 17, 2026, the Issuer's board of directors approved an option repricing (the "Repricing"), effective April 17, 2026 (the "Effective Date"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the "2015 Plan"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the "2020 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date. Read SEC document |
| April 17, 2026 Filed Apr 17, 2026 20:42 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | Disposition to issuerStock Option (Right to Buy) · Derivative | 113,300 | $0.00 Strike: $11.14 | $0.00 |
DisclosureSEC source: 0001746473-26-000054 · wk-form4_1776458561.xml · derivative · entry 13 Cummings Keith Lamont · CIK 0001809204 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 113,300 shares Expires 2035-01-23 F1 · kind: On April 17, 2026, the Issuer's board of directors approved an option repricing (the "Repricing"), effective April 17, 2026 (the "Effective Date"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the "2015 Plan"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the "2020 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date. Read SEC document |
| April 17, 2026 Filed Apr 17, 2026 20:42 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | GrantStock Option (Right to Buy) · Derivative | 110,500 | $0.00 Strike: $1.33 | $0.00 |
DisclosureSEC source: 0001746473-26-000054 · wk-form4_1776458561.xml · derivative · entry 12 Cummings Keith Lamont · CIK 0001809204 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,500 Underlying: Common Stock · 110,500 shares Expires 2034-01-23 F4 · derivative.exercise_price: The closing price per share of the Issuer's common stock on the Effective Date. Under the terms of the Repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends on the earliest of the following: (i) the eighteen-month anniversary of the Effective Date; (ii) the consummation of a Corporate Transaction (as defined by the 2015 Plan) or a Sale Event (as defined by the 2020 Plan); and (iii) the Reporting Person's (a) termination without cause (as defined in the Reporting Person's severance plan) or due to a reduction in force, (b) death or termination due to disability, or (c) resignation from service for good reason (as defined in the Reporting Person's severance plan). F5 · derivative.exercise_price: The repriced options will also revert to its original exercise price if the Reporting Person (i) is terminated for cause (as defined in the Reporting Person's severance Plan) or (ii) resigns prior to the end of the Retention Period, except for good reason (as defined in the Reporting Person's severance plan). F1 · kind: On April 17, 2026, the Issuer's board of directors approved an option repricing (the "Repricing"), effective April 17, 2026 (the "Effective Date"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the "2015 Plan"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the "2020 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date. Read SEC document |
| April 17, 2026 Filed Apr 17, 2026 20:42 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | Disposition to issuerStock Option (Right to Buy) · Derivative | 110,500 | $0.00 Strike: $17.44 | $0.00 |
DisclosureSEC source: 0001746473-26-000054 · wk-form4_1776458561.xml · derivative · entry 11 Cummings Keith Lamont · CIK 0001809204 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 110,500 shares Expires 2034-01-23 F1 · kind: On April 17, 2026, the Issuer's board of directors approved an option repricing (the "Repricing"), effective April 17, 2026 (the "Effective Date"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the "2015 Plan"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the "2020 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date. Read SEC document |
| April 17, 2026 Filed Apr 17, 2026 20:42 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | GrantStock Option (Right to Buy) · Derivative | 76,200 | $0.00 Strike: $1.33 | $0.00 |
DisclosureSEC source: 0001746473-26-000054 · wk-form4_1776458561.xml · derivative · entry 10 Cummings Keith Lamont · CIK 0001809204 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,200 Underlying: Common Stock · 76,200 shares Expires 2033-01-25 F4 · derivative.exercise_price: The closing price per share of the Issuer's common stock on the Effective Date. Under the terms of the Repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends on the earliest of the following: (i) the eighteen-month anniversary of the Effective Date; (ii) the consummation of a Corporate Transaction (as defined by the 2015 Plan) or a Sale Event (as defined by the 2020 Plan); and (iii) the Reporting Person's (a) termination without cause (as defined in the Reporting Person's severance plan) or due to a reduction in force, (b) death or termination due to disability, or (c) resignation from service for good reason (as defined in the Reporting Person's severance plan). F5 · derivative.exercise_price: The repriced options will also revert to its original exercise price if the Reporting Person (i) is terminated for cause (as defined in the Reporting Person's severance Plan) or (ii) resigns prior to the end of the Retention Period, except for good reason (as defined in the Reporting Person's severance plan). F1 · kind: On April 17, 2026, the Issuer's board of directors approved an option repricing (the "Repricing"), effective April 17, 2026 (the "Effective Date"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the "2015 Plan"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the "2020 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date. F9 · derivative.expiration_date: The expiration date has been updated from the Form 4 originally filed on January 27, 2023 from January 24, 2033 to the correct expiration date of January 25, 2033. Read SEC document |
| April 17, 2026 Filed Apr 17, 2026 20:42 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | Disposition to issuerStock Option (Right to Buy) · Derivative | 76,200 | $0.00 Strike: $34.65 | $0.00 |
DisclosureSEC source: 0001746473-26-000054 · wk-form4_1776458561.xml · derivative · entry 9 Cummings Keith Lamont · CIK 0001809204 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 76,200 shares Expires 2033-01-25 F1 · kind: On April 17, 2026, the Issuer's board of directors approved an option repricing (the "Repricing"), effective April 17, 2026 (the "Effective Date"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the "2015 Plan"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the "2020 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date. F9 · derivative.expiration_date: The expiration date has been updated from the Form 4 originally filed on January 27, 2023 from January 24, 2033 to the correct expiration date of January 25, 2033. Read SEC document |
| April 17, 2026 Filed Apr 17, 2026 20:42 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | GrantStock Option (Right to Buy) · Derivative | 124,000 | $0.00 Strike: $1.33 | $0.00 |
DisclosureSEC source: 0001746473-26-000054 · wk-form4_1776458561.xml · derivative · entry 8 Cummings Keith Lamont · CIK 0001809204 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 124,000 Underlying: Common Stock · 124,000 shares Expires 2032-01-26 F4 · derivative.exercise_price: The closing price per share of the Issuer's common stock on the Effective Date. Under the terms of the Repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends on the earliest of the following: (i) the eighteen-month anniversary of the Effective Date; (ii) the consummation of a Corporate Transaction (as defined by the 2015 Plan) or a Sale Event (as defined by the 2020 Plan); and (iii) the Reporting Person's (a) termination without cause (as defined in the Reporting Person's severance plan) or due to a reduction in force, (b) death or termination due to disability, or (c) resignation from service for good reason (as defined in the Reporting Person's severance plan). F5 · derivative.exercise_price: The repriced options will also revert to its original exercise price if the Reporting Person (i) is terminated for cause (as defined in the Reporting Person's severance Plan) or (ii) resigns prior to the end of the Retention Period, except for good reason (as defined in the Reporting Person's severance plan). F1 · kind: On April 17, 2026, the Issuer's board of directors approved an option repricing (the "Repricing"), effective April 17, 2026 (the "Effective Date"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the "2015 Plan"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the "2020 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date. F8 · derivative.expiration_date: The expiration date has been updated from the Form 4 originally filed on February 2, 2022 from January 25, 2032 to the correct expiration date of January 26, 2032. Read SEC document |
| April 17, 2026 Filed Apr 17, 2026 20:42 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | Disposition to issuerStock Option (Right to Buy) · Derivative | 124,000 | $0.00 Strike: $11.86 | $0.00 |
DisclosureSEC source: 0001746473-26-000054 · wk-form4_1776458561.xml · derivative · entry 7 Cummings Keith Lamont · CIK 0001809204 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 124,000 shares Expires 2032-01-26 F1 · kind: On April 17, 2026, the Issuer's board of directors approved an option repricing (the "Repricing"), effective April 17, 2026 (the "Effective Date"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the "2015 Plan"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the "2020 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date. F8 · derivative.expiration_date: The expiration date has been updated from the Form 4 originally filed on February 2, 2022 from January 25, 2032 to the correct expiration date of January 26, 2032. Read SEC document |
| April 17, 2026 Filed Apr 17, 2026 20:42 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | GrantStock Option (Right to Buy) · Derivative | 74,250 | $0.00 Strike: $1.33 | $0.00 |
DisclosureSEC source: 0001746473-26-000054 · wk-form4_1776458561.xml · derivative · entry 6 Cummings Keith Lamont · CIK 0001809204 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,250 Underlying: Common Stock · 74,250 shares Expires 2031-01-23 F4 · derivative.exercise_price: The closing price per share of the Issuer's common stock on the Effective Date. Under the terms of the Repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends on the earliest of the following: (i) the eighteen-month anniversary of the Effective Date; (ii) the consummation of a Corporate Transaction (as defined by the 2015 Plan) or a Sale Event (as defined by the 2020 Plan); and (iii) the Reporting Person's (a) termination without cause (as defined in the Reporting Person's severance plan) or due to a reduction in force, (b) death or termination due to disability, or (c) resignation from service for good reason (as defined in the Reporting Person's severance plan). F5 · derivative.exercise_price: The repriced options will also revert to its original exercise price if the Reporting Person (i) is terminated for cause (as defined in the Reporting Person's severance Plan) or (ii) resigns prior to the end of the Retention Period, except for good reason (as defined in the Reporting Person's severance plan). F1 · kind: On April 17, 2026, the Issuer's board of directors approved an option repricing (the "Repricing"), effective April 17, 2026 (the "Effective Date"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the "2015 Plan"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the "2020 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date. F7 · derivative.expiration_date: The expiration date has been updated from the Form 4 originally filed on January 26, 2021 from January 22, 2031 to the correct expiration date of January 23, 2031. Read SEC document |
| April 17, 2026 Filed Apr 17, 2026 20:42 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | Disposition to issuerStock Option (Right to Buy) · Derivative | 74,250 | $0.00 Strike: $26.50 | $0.00 |
DisclosureSEC source: 0001746473-26-000054 · wk-form4_1776458561.xml · derivative · entry 5 Cummings Keith Lamont · CIK 0001809204 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 74,250 shares Expires 2031-01-23 F1 · kind: On April 17, 2026, the Issuer's board of directors approved an option repricing (the "Repricing"), effective April 17, 2026 (the "Effective Date"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the "2015 Plan"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the "2020 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date. F7 · derivative.expiration_date: The expiration date has been updated from the Form 4 originally filed on January 26, 2021 from January 22, 2031 to the correct expiration date of January 23, 2031. Read SEC document |
| April 17, 2026 Filed Apr 17, 2026 20:42 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | GrantStock Option (Right to Buy) · Derivative | 18,198 | $0.00 Strike: $1.33 | $0.00 |
DisclosureSEC source: 0001746473-26-000054 · wk-form4_1776458561.xml · derivative · entry 4 Cummings Keith Lamont · CIK 0001809204 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,198 Underlying: Common Stock · 18,198 shares Expires 2030-03-31 F4 · derivative.exercise_price: The closing price per share of the Issuer's common stock on the Effective Date. Under the terms of the Repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends on the earliest of the following: (i) the eighteen-month anniversary of the Effective Date; (ii) the consummation of a Corporate Transaction (as defined by the 2015 Plan) or a Sale Event (as defined by the 2020 Plan); and (iii) the Reporting Person's (a) termination without cause (as defined in the Reporting Person's severance plan) or due to a reduction in force, (b) death or termination due to disability, or (c) resignation from service for good reason (as defined in the Reporting Person's severance plan). F5 · derivative.exercise_price: The repriced options will also revert to its original exercise price if the Reporting Person (i) is terminated for cause (as defined in the Reporting Person's severance Plan) or (ii) resigns prior to the end of the Retention Period, except for good reason (as defined in the Reporting Person's severance plan). F1 · kind: On April 17, 2026, the Issuer's board of directors approved an option repricing (the "Repricing"), effective April 17, 2026 (the "Effective Date"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the "2015 Plan"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the "2020 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date. F6 · derivative.expiration_date: The expiration date has been updated from the Form 3 originally filed on June 2, 2020 from March 30, 2030 to the correct expiration date of March 31, 2030. Read SEC document |
| April 17, 2026 Filed Apr 17, 2026 20:42 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | Disposition to issuerStock Option (Right to Buy) · Derivative | 18,198 | $0.00 Strike: $6.22 | $0.00 |
DisclosureSEC source: 0001746473-26-000054 · wk-form4_1776458561.xml · derivative · entry 3 Cummings Keith Lamont · CIK 0001809204 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,198 shares Expires 2030-03-31 F1 · kind: On April 17, 2026, the Issuer's board of directors approved an option repricing (the "Repricing"), effective April 17, 2026 (the "Effective Date"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the "2015 Plan"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the "2020 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date. F6 · derivative.expiration_date: The expiration date has been updated from the Form 3 originally filed on June 2, 2020 from March 30, 2030 to the correct expiration date of March 31, 2030. Read SEC document |
| April 17, 2026 Filed Apr 17, 2026 20:42 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | GrantStock Option (Right to Buy) · Derivative | 76,047 | $0.00 Strike: $1.33 | $0.00 |
DisclosureSEC source: 0001746473-26-000054 · wk-form4_1776458561.xml · derivative · entry 2 Cummings Keith Lamont · CIK 0001809204 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,047 Underlying: Common Stock · 76,047 shares Expires 2029-01-24 F4 · derivative.exercise_price: The closing price per share of the Issuer's common stock on the Effective Date. Under the terms of the Repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends on the earliest of the following: (i) the eighteen-month anniversary of the Effective Date; (ii) the consummation of a Corporate Transaction (as defined by the 2015 Plan) or a Sale Event (as defined by the 2020 Plan); and (iii) the Reporting Person's (a) termination without cause (as defined in the Reporting Person's severance plan) or due to a reduction in force, (b) death or termination due to disability, or (c) resignation from service for good reason (as defined in the Reporting Person's severance plan). F5 · derivative.exercise_price: The repriced options will also revert to its original exercise price if the Reporting Person (i) is terminated for cause (as defined in the Reporting Person's severance Plan) or (ii) resigns prior to the end of the Retention Period, except for good reason (as defined in the Reporting Person's severance plan). F1 · kind: On April 17, 2026, the Issuer's board of directors approved an option repricing (the "Repricing"), effective April 17, 2026 (the "Effective Date"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the "2015 Plan"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the "2020 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date. F3 · derivative.expiration_date: The expiration date has been updated from the Form 3 originally filed on June 2, 2020 from January 23, 2029 to the correct expiration date of January 24, 2029. Read SEC document |
| April 17, 2026 Filed Apr 17, 2026 20:42 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | Disposition to issuerStock Option (Right to Buy) · Derivative | 76,047 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0001746473-26-000054 · wk-form4_1776458561.xml · derivative · entry 1 Cummings Keith Lamont · CIK 0001809204 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 76,047 shares Expires 2029-01-24 F1 · kind: On April 17, 2026, the Issuer's board of directors approved an option repricing (the "Repricing"), effective April 17, 2026 (the "Effective Date"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the "2015 Plan"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the "2020 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date. F3 · derivative.expiration_date: The expiration date has been updated from the Form 3 originally filed on June 2, 2020 from January 23, 2029 to the correct expiration date of January 24, 2029. Read SEC document |
| January 22, 2026 Filed Jan 26, 2026 21:36 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | GrantStock Option (Right to Buy) · Derivative | 400,000 | $0.00 Strike: $1.30 | $0.00 |
DisclosureSEC source: 0001746473-26-000020 · wk-form4_1769463411.xml · derivative · entry 1 Cummings Keith Lamont · CIK 0001809204 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2036-01-22 F1 · derivative.exercise_date: 1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of January 1, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| January 20, 2026 Filed Jan 23, 2026 02:46 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | SaleCommon Stock | 24,002 | $1.28 | $30,722.56 |
DisclosureSEC source: 0001746473-26-000012 · wk-form4_1769136395.xml · nonDerivative · entry 1 Cummings Keith Lamont · CIK 0001809204 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 297,214 F1 · price: Represents a nondiscretionary sale by the plan on behalf of the Reporting Person in a manner intended to satisfy the requirements of Rule 10b5-1. The sale price of the Reporting Person's share represents the weighted average of all shares sold by a broker at prices ranging from $1.245 to $1.33, inclusive, on January 20, 2026 through January 22, 2026 on behalf of a group on employees of the Issuer, including the Reporting Person, to satisfy the payment of withholding tax liability in connection with the vesting of previously granted restricted stock units. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (1) to this Form 4. F2 · balance_after: Includes 1,958 shares of Common Stock acquired by the Reporting Person pursuant to an Employee Stock Purchase Plan program. Read SEC document |
| January 23, 2025 Filed Jan 27, 2025 23:01 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | GrantStock Option (Right to Buy) · Derivative | 113,300 | $0.00 Strike: $11.14 | $0.00 |
DisclosureSEC source: 0001746473-25-000011 · wk-form4_1738018892.xml · derivative · entry 2 Cummings Keith Lamont · CIK 0001809204 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,300 Underlying: Common Stock · 113,300 shares Expires 2035-01-23 F2 · derivative.exercise_date: 1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of January 1, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| January 23, 2025 Filed Jan 27, 2025 23:01 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | GrantCommon Stock | 56,650 | $0.00 | $0.00 |
DisclosureSEC source: 0001746473-25-000011 · wk-form4_1738018892.xml · nonDerivative · entry 1 Cummings Keith Lamont · CIK 0001809204 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 319,258 F1 · shares: These are restricted stock units that vest in three substantially equal annual installments beginning January 16, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| January 17, 2025 Filed Jan 22, 2025 23:05 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | SaleCommon Stock | 20,148 | $11.20 | $225,679.76 |
DisclosureSEC source: 0001746473-25-000005 · wk-form4_1737587121.xml · nonDerivative · entry 1 Cummings Keith Lamont · CIK 0001809204 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 262,608 F1 · price: Represents a nondiscretionary sale by the plan on behalf of the Reporting Person in a manner intended to satisfy the requirements of Rule 10b5-1. The sale price of the Reporting Person's shares represents the weighted average of all shares sold by a broker at prices ranging from $11.03 to $11.695, inclusive, on January 17, 2025 and January 21, 2025 on behalf of a group of employees of the Issuer, including the Reporting Person, to satisfy the payment of withholding tax liability in connection with the vesting of previously granted restricted stock units. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (1) to this Form 4. F2 · balance_after: Includes 641 shares of Common Stock acquired by the Reporting Person pursuant to an Employee Stock Purchase Plan program. Read SEC document |
| July 10, 2024 Filed Jul 12, 2024 22:37 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | SaleCommon Stock | 10,911 | $11.56 | $126,131.16 |
DisclosureSEC source: 0001746473-24-000125 · wk-form4_1720823841.xml · nonDerivative · entry 1 Cummings Keith Lamont · CIK 0001809204 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 282,115 F1 · price: Represents a nondiscretionary sale by the plan on behalf of the Reporting Person in a manner intended to satisfy the requirements of Rule 10b5-1. The sale price of the Reporting Person's shares represents the weighted average of all shares sold by a broker at prices ranging from $10.785 to $12.58, inclusive, between July 10, 2024 and July 11, 2024 on behalf of a group of employees of the Issuer, including the Reporting Person, to satisfy the payment of withholding tax liability in connection with the vesting of previously granted performance-vested stock units. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (1) to this Form 4. Read SEC document |
| July 09, 2024 Filed Jul 11, 2024 20:54 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | GrantCommon Stock | 21,313 | $0.00 | $0.00 |
DisclosureSEC source: 0001746473-24-000115 · wk-form4_1720731247.xml · nonDerivative · entry 1 Cummings Keith Lamont · CIK 0001809204 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 293,026 F1 · shares: On July 28, 2022, the Reporting Person was granted 77,500 performance-vested stock units, the vesting of which were subject to the achievement of various pre-established performance criteria. On July 9, 2024, the Compensation Committee of the Issuer's Board of Directors certified the achievement of the performance criteria tied to the company's total shareholder return relative to the Nasdaq Biotechnology Index, resulting in the vesting of 21,313 shares. Read SEC document |
| May 02, 2024 Filed May 6, 2024 10:02 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | Exercise / conversionStock Option (Right to Buy) · Derivative | 21,000 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0001746473-24-000063 · wk-form4_1714989755.xml · derivative · entry 2 Cummings Keith Lamont · CIK 0001809204 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,047 Underlying: Common Stock · 21,000 shares Expires 2029-01-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of the shares subject to such option vested on December 31, 2019 and 1/48th of the shares subject to the option vested in substantially equal monthly installments thereafter, all of which were subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| May 02, 2024 Filed May 6, 2024 10:02 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | Exercise / conversionCommon Stock | 21,000 | $2.08 | $43,680.00 |
DisclosureSEC source: 0001746473-24-000063 · wk-form4_1714989755.xml · nonDerivative · entry 1 Cummings Keith Lamont · CIK 0001809204 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 271,713 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 858 shares of Common Stock acquired by the Reporting Person pursuant to an Employee Stock Purchase Plan program. Read SEC document |
| January 23, 2024 Filed Jan 24, 2024 21:57 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | GrantStock Option (Right to Buy) · Derivative | 110,500 | $0.00 Strike: $17.44 | $0.00 |
DisclosureSEC source: 0001746473-24-000014 · wk-form4_1706133428.xml · derivative · entry 2 Cummings Keith Lamont · CIK 0001809204 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,500 Underlying: Common Stock · 110,500 shares Expires 2034-01-23 F2 · derivative.exercise_date: 1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of January 1, 2024, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| January 23, 2024 Filed Jan 24, 2024 21:57 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | GrantCommon Stock | 55,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001746473-24-000014 · wk-form4_1706133428.xml · nonDerivative · entry 1 Cummings Keith Lamont · CIK 0001809204 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 249,855 F1 · shares: These are restricted stock units that vest in three substantially equal annual installments beginning January 16, 2024, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| January 17, 2024 Filed Jan 19, 2024 22:19 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | SaleCommon Stock | 9,781 | $17.23 | $168,526.63 |
DisclosureSEC source: 0001746473-24-000005 · wk-form4_1705702764.xml · nonDerivative · entry 1 Cummings Keith Lamont · CIK 0001809204 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 194,605 F1 · price: Represents a nondiscretionary sale by the plan on behalf of the Reporting Person in a manner intended to satisfy the requirements of Rule 10b5-1. The sale price of the Reporting Person's shares represents the weighted average of all shares sold by a broker at prices ranging from $16.33 to $17.90, inclusive, between January 17, 2024 and January 18, 2024 on behalf of a group of employees of the Issuer, including the Reporting Person, to satisfy the payment of withholding tax liability in connection with the vesting of previously granted restricted stock units. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (1) to this Form 4. F2 · balance_after: Includes 387 shares of Common Stock acquired by the Reporting Person pursuant to an Employee Stock Purchase Plan program. Read SEC document |
| July 17, 2023 Filed Jul 20, 2023 00:23 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | SaleCommon Stock | 19,771 | $18.01 | $356,057.92 |
DisclosureSEC source: 0001209191-23-042825 · doc4.xml · nonDerivative · entry 1 Cummings Keith Lamont · CIK 0001809204 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 203,999 F1 · price: Represents a nondiscretionary sale by the plan on behalf of the Reporting Person in a manner intended to satisfy the requirements of Rule 10b5-1. The sale price of the Reporting Person's shares represents the weighted average of all shares sold by a broker at prices ranging from $17.63 to $18.47, inclusive, between July 17, 2023 and July 19, 2023 on behalf of a group of employees of the Issuer, including the Reporting Person, to satisfy the payment of withholding tax liability in connection with the vesting of previously granted performance-vested stock units. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (1) to this Form 4. Read SEC document |
| July 14, 2023 Filed Jul 18, 2023 23:17 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | GrantCommon Stock | 38,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-042656 · doc4.xml · nonDerivative · entry 1 Cummings Keith Lamont · CIK 0001809204 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 223,770 F1 · shares: On July 28, 2022, the Reporting Person was granted 77,500 performance-vested stock units, the vesting of which are subject to the achievement of various pre-established performance criteria. On July 14, 2023, the Compensation Committee of the Issuer's Board of Directors certified the achievement of an operational performance criteria, resulting in the vesting of 38,750 shares. Read SEC document |
| June 13, 2023 Filed Jun 14, 2023 22:14 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | Exercise / conversionStock Option (Right to Buy) · Derivative | 30,750 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0001209191-23-037143 · doc4.xml · derivative · entry 2 Cummings Keith Lamont · CIK 0001809204 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,047 Underlying: Common Stock · 30,750 shares Expires 2029-01-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the shares subject to such option vested on December 31, 2019 and 1/48th of the shares subject to the option vested in substantially equal monthly installments thereafter, all of which were subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| June 13, 2023 Filed Jun 14, 2023 22:14 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | Exercise / conversionCommon Stock | 30,750 | $2.08 | $63,960.00 |
DisclosureSEC source: 0001209191-23-037143 · doc4.xml · nonDerivative · entry 1 Cummings Keith Lamont · CIK 0001809204 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 185,020 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 09, 2023 Filed Jun 12, 2023 22:19 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,800 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0001209191-23-036465 · doc4.xml · derivative · entry 2 Cummings Keith Lamont · CIK 0001809204 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 127,797 Underlying: Common Stock · 5,800 shares Expires 2029-01-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the shares subject to such option vested on December 31, 2019 and 1/48th of the shares subject to the option vested in substantially equal monthly installments thereafter, all of which were subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| June 09, 2023 Filed Jun 12, 2023 22:19 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | Exercise / conversionCommon Stock | 5,800 | $2.08 | $12,064.00 |
DisclosureSEC source: 0001209191-23-036465 · doc4.xml · nonDerivative · entry 1 Cummings Keith Lamont · CIK 0001809204 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 154,270 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 30, 2023 Filed Apr 3, 2023 22:48 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | SaleCommon Stock | 9,960 | $26.52 | $264,148.16 |
DisclosureSEC source: 0001209191-23-022364 · doc4.xml · nonDerivative · entry 1 Cummings Keith Lamont · CIK 0001809204 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 148,470 F1 · price: Represents a nondiscretionary sale by the plan established on behalf of the Reporting Person on July 28, 2022 in a manner intended to satisfy the requirements of Rule 10b5-1. The sale price of the Reporting Person's shares represents the weighted average of all shares sold by a broker at prices ranging from $25.88 to $27.235, inclusive, on March 30, 2023 and March 31, 2023 on behalf of a group of employees of the Issuer, including the Reporting Person, to satisfy the payment of withholding tax liability in connection with the vesting of previously granted performance-vested stock units. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (1) to this Form 4. Read SEC document |
| March 29, 2023 Filed Mar 31, 2023 21:56 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | GrantCommon Stock | 19,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-021917 · doc4.xml · nonDerivative · entry 1 Cummings Keith Lamont · CIK 0001809204 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 158,430 F1 · shares: On July 28, 2022, the Reporting Person was granted 77,500 performance-vested stock units, the vesting of which are subject to the achievement of various pre-established performance criteria. On March 29, 2023, the Compensation Committee of the Issuer's Board of Directors certified the achievement of an operational performance criteria, resulting in the vesting of 19,375 shares. F2 · balance_after: Includes 631 shares of Common Stock acquired by the Reporting Person pursuant to an Employee Stock Purchase Plan program. Read SEC document |
| January 25, 2023 Filed Jan 28, 2023 00:15 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | GrantStock Option (right to buy) · Derivative | 76,200 | $0.00 Strike: $34.65 | $0.00 |
DisclosureSEC source: 0001140361-23-003181 · form4.xml · derivative · entry 2 Cummings Keith Lamont · CIK 0001809204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,200 Underlying: Common Stock · 76,200 shares Expires 2033-01-24 F2 · derivative.exercise_date: 1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of January 1, 2023, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| January 25, 2023 Filed Jan 28, 2023 00:15 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | GrantCommon Stock | 54,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-003181 · form4.xml · nonDerivative · entry 1 Cummings Keith Lamont · CIK 0001809204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,424 F1 · shares: These are restricted stock units that vest in three equal annual installments beginning January 16, 2023, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| January 23, 2023 Filed Jan 26, 2023 02:00 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | Exercise / conversionStock Option (right to buy) · Derivative | 17,500 | $0.00 Strike: $6.22 | $0.00 |
DisclosureSEC source: 0001140361-23-002783 · form4.xml · derivative · entry 5 Cummings Keith Lamont · CIK 0001809204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,198 Underlying: Common Stock · 17,500 shares Expires 2030-03-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of March 31, 2020 (or if there is no corresponding day in any such month, on the last day of such month), subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| January 23, 2023 Filed Jan 26, 2023 02:00 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | Exercise / conversionStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0001140361-23-002783 · form4.xml · derivative · entry 4 Cummings Keith Lamont · CIK 0001809204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,597 Underlying: Common Stock · 12,500 shares Expires 2029-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of the shares subject to such option vested on December 31, 2019 and 1/48th of the shares subject to the option vest in substantially equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| January 23, 2023 Filed Jan 26, 2023 02:00 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | SaleCommon Stock | 30,000 | $35.00 | $1,050,000.00 |
DisclosureSEC source: 0001140361-23-002783 · form4.xml · nonDerivative · entry 3 Cummings Keith Lamont · CIK 0001809204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,424 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 5, 2021, as amended on August 29, 2022. Read SEC document |
| January 23, 2023 Filed Jan 26, 2023 02:00 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | Exercise / conversionCommon Stock | 17,500 | $6.22 | $108,850.00 |
DisclosureSEC source: 0001140361-23-002783 · form4.xml · nonDerivative · entry 2 Cummings Keith Lamont · CIK 0001809204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,424 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 23, 2023 Filed Jan 26, 2023 02:00 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | Exercise / conversionCommon Stock | 12,500 | $2.08 | $26,000.00 |
DisclosureSEC source: 0001140361-23-002783 · form4.xml · nonDerivative · entry 1 Cummings Keith Lamont · CIK 0001809204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,924 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 22, 2022 Filed Dec 27, 2022 21:30 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | Exercise / conversionStock Option (right to buy) · Derivative | 4,000 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0001140361-22-047041 · form4.xml · derivative · entry 2 Cummings Keith Lamont · CIK 0001809204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,097 Underlying: Common Stock · 4,000 shares Expires 2029-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the shares subject to such option vested on December 31, 2019 and 1/48th of the shares subject to the option vest in substantially equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| December 22, 2022 Filed Dec 27, 2022 21:30 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | Exercise / conversionCommon Stock | 4,000 | $2.08 | $8,320.00 |
DisclosureSEC source: 0001140361-22-047041 · form4.xml · nonDerivative · entry 1 Cummings Keith Lamont · CIK 0001809204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,424 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 20, 2022 Filed Dec 22, 2022 02:32 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | SaleCommon Stock | 9,643 | $19.10 | $184,204.44 |
DisclosureSEC source: 0001140361-22-046571 · form4.xml · nonDerivative · entry 2 Cummings Keith Lamont · CIK 0001809204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,424 F3 · price: The sale price of the Reporting Person's shares represents the weighted average price of all shares sold by a broker at prices ranging from $18.4049 to $19.64, inclusive, on December 20, 2022 and December 21, 2022 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee in connection with the vesting of previously granted performance-vested stock units. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (3) to this Form 4. Read SEC document |
| December 19, 2022 Filed Dec 22, 2022 02:32 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | GrantCommon Stock | 19,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-22-046571 · form4.xml · nonDerivative · entry 1 Cummings Keith Lamont · CIK 0001809204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,067 F1 · shares: On July 28, 2022, the Reporting Person was granted 77,500 performance-vested stock units, the vesting of which are subject to the achievement of various pre-established performance criteria. On December 19, 2022, the Compensation Committee of the Issuer's Board of Directors certified the achievement of an operational performance criteria, resulting in the vesting of 19,375 shares. F2 · balance_after: Includes 3,071 shares of Common Stock acquired by the Reporting Person pursuant to an employee stock purchase program. Read SEC document |
| January 26, 2022 Filed Feb 3, 2022 01:15 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | GrantStock Option (right to buy) · Derivative | 124,000 | $0.00 Strike: $11.86 | $0.00 |
DisclosureSEC source: 0001567619-22-002400 · doc1.xml · derivative · entry 1 Cummings Keith Lamont · CIK 0001809204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,000 Underlying: Common Stock · 124,000 shares Expires 2032-01-25 F1 · derivative.exercise_date: 1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of January 1, 2022, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| September 03, 2021 Filed Sep 3, 2021 22:27 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0001209191-21-054876 · doc4.xml · derivative · entry 2 Cummings Keith Lamont · CIK 0001809204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,097 Underlying: Common Stock · 20,000 shares Expires 2029-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the shares subject to such option vested on December 31, 2019 and 1/48th of the shares subject to the option vest in substantially equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| September 03, 2021 Filed Sep 3, 2021 22:27 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | Exercise / conversionCommon Stock | 20,000 | $2.08 | $41,600.00 |
DisclosureSEC source: 0001209191-21-054876 · doc4.xml · nonDerivative · entry 1 Cummings Keith Lamont · CIK 0001809204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,621 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 05, 2021 Filed Mar 6, 2021 01:51 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0001209191-21-018434 · doc4.xml · derivative · entry 2 Cummings Keith Lamont · CIK 0001809204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,097 Underlying: Common Stock · 20,000 shares Expires 2029-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the shares subject to such option vested on December 31, 2019 and 1/48th of the shares subject to the option vest in substantially equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| March 05, 2021 Filed Mar 6, 2021 01:51 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | Exercise / conversionCommon Stock | 20,000 | $2.08 | $41,600.00 |
DisclosureSEC source: 0001209191-21-018434 · doc4.xml · nonDerivative · entry 1 Cummings Keith Lamont · CIK 0001809204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,621 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.